vedolizumab,doxorubicin,prednisone,polatuzumab vedotin,etoposide,rituximab,cyclophosphamide
teva,roche,takeda
['doxorubicin', 'fil,veral,12', 'dlbcl', 'etoposide', 'lymphoma', 'nct03274492', 'prednisone', ' vedo', 'cyclophosphamide', 'polatuzumab', 'polarix', 'ritux']
congress | #ash22
fr d ric boissard, presents analysis from the ploarix study about the epidemiological impact of pola-r-chp use in untreated #dlbcl in terms of 2l treatment. it was suggested that using pola-r-chp as 1l therapy reduced the overall treatment burden for patients. 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm